Viatris Comes Out Swinging At Unsolicited Mini-Tender Offer
TRC Capital Makes Discounted Offer For Millions Of Shares
TRC Capital Corporation, famed for making discounted offers to buy shares well below the SEC’s 5% threshold, has approached Viatris shareholders. The newly-formed company, like many others, has urged shareholders to say no.
You may also be interested in...
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).
Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.